Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared a post on LinkedIn about a paper he co-authored with his colleagues published in Radiotherapy and Oncology:
“Important collaboration between ESMO – European Society for Medical Oncology and European Society for Radiotherapy and Oncology (ESTRO) on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.”
Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.
Authors: Evert S.M. van Aken, Ajeet Kumar Gandhi, Sean M. O’Cathail, Gerben Borst, Jorge Barriuso, Emmanouil Fokas, Luis Castelo-Branco, Anne Hansen Reek, Evandro de Azambuja, Stephanie Kroezem, Ilaria Colombo, Antonin Levy, Carmen Criscitiello, Maximilian Niyazi, Nadia Harbeck, Ewa Szutowicz, Gabor Liposits, Marcel Verheij, Isabelle Ray-Coquard, Paolo Tarantino, Dario Trapani, Paulien Boot, Claus Belka, Dirk De Ruysscher, George Pentheroudakis, Corrie A.M. Marijnen, Florian Lordick, Umberto Ricardi, Diogo Martins-Branco, Arsela Prelaji, Monique C. de Jong, and Bharti Devnani.
You can read the full article in Radiotherapy and Oncology.
More posts featuring Evandro de Azambuja.